Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Gastrointestinal Stromal Tumors × tanespimycin × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gastrointestinal 1

Conditions

Multiple Myeloma 1 Gastrointestinal Stromal Tumors 1

Interventions

Imatinib Mesylate 17 Sunitinib 8 nilotinib 4 ripretinib 3 masitinib 2 tanespimycin 1 regorafenib 1 famitinib 1 Sodium Chloride 1 Immunoglobulin G 1 IDRX-42 1 Fentanyl 1 Disulfides 1 Carnitine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00688766 2012-12-11

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Infinity Pharmaceuticals, Inc.

Phase 3 Terminated

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡